Biomarkers.

Background: Blood-based biomarkers offer a cost-effective and simple alternative for clinical use in the context of Alzheimer's disease (AD). It has already been shown that plasma phosphorylated tau at threonine 217 (p-tau217) is associated with amyloid (Aβ), neurofibrillary tau tangles, and cognitive decline. Longitudinal studies confirmed its ability to track AD progression.

Biomarkers.

Background: Recent anti-amyloid clinical trials have incorporated plasma glial fibrillary acidic protein (GFAP) as an exploratory endpoint, reporting a notable decrease in plasma GFAP levels over time. Additionally, plasma GFAP has been associated with Aβ pathology and cognitive decline in individuals with cognitive impairment, making it a robust biomarker of neuroinflammation for Alzheimer's disease (AD). Here, we tested the utility of changes in plasma GFAP as a secondary endpoint in AD clinical trials focusing on cognitively impaired (CI) individuals.

Public Health.

Background: The optimal combinations of modifiable risk factors to be targeted in preventive dementia trials may vary across countries and settings. We aimed to identify the combinations of modifiable risk factors associated with cognitive change in Canadian adults.

Method: Population Attributable Fraction analyses on 30,097 participants from the Canadian Longitudinal Study on Aging and prevalence of 2, 3 and 4 risk combinations of the 12 modifiable risk factors identified in the 2020 Dementia Lancet report were estimated to note the ten most prevalent combinations.

Biomarkers.

Background: We aimed to clarify the role of physical activity patterns on cognitive function decline caused by white matter structure alteration following the progression of Alzheimer's disease(AD). Physical activity has been reported as having a close association with various pathological factor of dementia, especially it has been proved as a protective factor of disease advancement. Comparing the mediating models between Mild Cognitive Impairment (MCI) and AD, we aspire to elucidate how activity patterns, as a biomarker, undergo progression in the pathogenesis of the disease.

Biomarkers.

Background: Blood-based biomarkers for Alzheimer's disease (AD) are increasingly prevalent and accessible beyond research environments. Consequently, it is crucial to determine whether confounding factors, particularly highly prevalent comorbidities, influence the levels of these blood biomarkers, thereby refining their clinical interpretation. In this study, we examined the impact of comorbidities on plasma AD biomarker levels within a memory-clinic cohort.